BRAF and central nervous system cancer: Selectively, some of them include the evaluation of the dabrafenib plus trametinib combination in pLGGs [114], which paved the way for the FDA approval of this combination for treatment, the investigation of the effectiveness of selumetinib in NF1-associated gliomas [96], and the study of the role of tovorafenib in relapsed pLGG with BRAF alterations (FIREFLY-1/NCT04775485) [130].